Voyager Therapeutics, CHDI Foundation deal

Voyager and CHDI partnered to advance Voyager’s VY-HTT01 into clinical trials to treat Huntington’s disease (HD). CHDI will provide funding to support an IND submission and a Phase I trial. CHDI will ...